Given the potent anti-tumor abilities of both CD8+ T cells and cancer cell ferroptosis, constructing nanopolymer drugs containing CD8+ T cell activators and ferroptosis targets can simultaneously activate CD8+ T cells and promote cancer cell ferroptosis, thereby amplifying the tumor therapeutic effects. The gene discussed is CD8A; the disease is cancer.